GETTING YOUR PATIENTS STARTED ON VIVITROL

Your office can order VIVITROL directly from a distributor or through a pharmacy (specialty or other).

This brochure will assist with:

- Specialty pharmacy process
- Buy-and-bill process
- VIVITROL® Co-pay Savings Program

Please see Important Safety Information on page 9. Also see Prescribing Information and Medication Guide. Review the Medication Guide with your patients.
**ORDERING VIVITROL**

**(NALTREXONE FOR EXTENDED-RELEASE INJECTABLE SUSPENSION)**

**FROM A SPECIALTY PHARMACY**

When ordering VIVITROL, you can work directly with a pharmacy (specialty or other) or you can work with a Vivitrol2gether™ dedicated case manager. With Vivitrol2gether, you choose the VIVITROL fulfillment features that work best to support your patients.

**Option 1: Order directly from a specialty pharmacy**

If you’re ordering VIVITROL directly from a specialty pharmacy, fax ALL of the following documents to the selected pharmacy:

- Copy of the signed VIVITROL prescription
- Prior Authorization Form (if applicable)
- Photocopy of the front and back of the patient’s insurance card (enlarged to ensure legibility)
- Printed co-pay card* (available at VIVITROLCopay.com)

**Option 2: Work with a dedicated case manager**

You can also work directly with a dedicated case manager for assistance in fulfilling VIVITROL prescriptions. Fax ALL of the following documents to Vivitrol2gether Support Services at 1-877-329-8484:

- Vivitrol2gether Support Services Enrollment Form (an editable PDF version of the Vivitrol2gether Support Services Patient Enrollment Form can be downloaded at VIVITROL.com)
- Photocopy of the front and back of the patient’s insurance card (enlarged to ensure legibility)
- Prior Authorization Form (if applicable)

Vivitrol2gether Support Services is a resource designed to help patients with:

- Reimbursement coverage verification
- Submission of VIVITROL prescriptions to a pharmacy (specialty or other)
- Submission of VIVITROL co-pay assistance for eligible patients*
- Patient transition services

**CRITICAL**

- Fax the PA form (if needed) and an enlarged photocopy of the patient’s pharmacy and health insurance cards to the health insurer’s toll-free fax number on the PA form. Pharmacies and health insurers typically prefer that these items come directly from your office.
- **Follow up within 24 hours to ensure the prescription is being processed.**
  - Remember to identify the date of the scheduled injection.
  - If the specialty pharmacy cannot process the prescription for VIVITROL, consider enrolling your patient into Vivitrol2gether to receive pharmacy routing assistance.

Please see Important Safety Information on page 9. Also see Prescribing Information and Medication Guide. Review the Medication Guide with your patients.
THE SPECIALTY PHARMACY PROCESS FLOW

Whether you have elected to send the prescription directly to the pharmacy (specialty or other) or have chosen to go through Vivitol2getherSM, there are certain tasks that the specialty pharmacy will perform once you or your staff have completed the relevant forms.

1. First VIVITROL® (naltrexone for extended-release injectable suspension) prescription
   - Determine the specialty or other pharmacy options available based on the patient’s health plan coverage
   - Discuss the VIVITROL® Co-pay Savings Program with the patient; eligible patients can sign up and provide the required information to the pharmacy
   - Remind your patients to expect a call from the pharmacy and/or nurse coordinator to review important information about the first pharmacy order

2. Insurance, Co-pay Savings and Prescription Verification
   - Specialty or other pharmacy performs a benefit verification on behalf of the patient and confirms prescription verification and prior authorization with the health plan
   - Co-pay savings are applied for eligible patients
   - Patient authorizes payment

3. Schedule shipping and delivery
   - Patient is contacted to schedule or confirm delivery date
   - Patient is called about next steps and follow-up

4. Rx is filled and ready to ship
   - Pharmacy contacts patient and provider’s office to authorize shipment
     - After patient authorization, pharmacy will contact your office to set up delivery
   - Prescription is filled by pharmacy and shipped to your office

5. Delivery of VIVITROL
   - Office receives VIVITROL
   - Patient receives injection of VIVITROL
   - Your patient’s follow-up appointment is scheduled

6. Follow-up for next injection
   - Schedule follow-up appointment for the next injection

Suggestions to help improve fill time
- Learn which pharmacies (specialty or other) work with your patients’ health plans
- Establish a relationship with the specialty pharmacy contact person and determine the best way for you to communicate (e.g., phone, email, or fax)
- Follow up regularly and be sure to communicate the required injection date of VIVITROL for each patient

Please see Important Safety Information on page 9. Also see Prescribing Information and Medication Guide. Review the Medication Guide with your patients.
ORDERING VIVITROL®
(NALTREXONE FOR EXTENDED-RELEASE INJECTABLE SUSPENSION)
THROUGH BUY-AND-BILL

VIVITROL® Provider Pricing Program
Direct-purchase discount is available to eligible* providers through Besse Medical and Smith Medical Partners, the Alkermes-preferred distribution partners.

Available pricing
- For eligible* providers available through Besse Medical and Smith Medical Partners
- Single- and multiple-carton contract pricing discount
  - 10% to 18% off wholesale acquisition cost (WAC) based on quantity purchased
- Extended payment terms of 75 days
  - Accommodates reimbursement timing

<table>
<thead>
<tr>
<th>Description</th>
<th>NDC 10</th>
<th>NDC 11</th>
<th>Strength (Package Size)</th>
<th>Order Quantity</th>
<th>Discount Price (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VIVITROL 380-mg vial</td>
<td>65757-300-01</td>
<td>65757-0300-01</td>
<td>380-mg vial</td>
<td>1 to 4 units†</td>
<td>WAC — 10%</td>
</tr>
<tr>
<td>VIVITROL 380-mg vial</td>
<td>65757-300-01</td>
<td>65757-0300-01</td>
<td>380-mg vial</td>
<td>5 to 24 units†</td>
<td>WAC — 15%</td>
</tr>
<tr>
<td>VIVITROL 380-mg vial</td>
<td>65757-300-01</td>
<td>65757-0300-01</td>
<td>380-mg vial</td>
<td>25 or more units†</td>
<td>WAC — 18%</td>
</tr>
</tbody>
</table>

*Contact Besse Medical or Smith Medical Partners regarding eligibility for program pricing.
Uninsured program pricing is not available through Smith Medical Partners.
†One unit contains 1 dose of VIVITROL.

Please see Important Safety Information on page 9. Also see Prescribing Information and Medication Guide. Review the Medication Guide with your patients.
To get started with VIVITROL® Provider Pricing Program, set up an account with your chosen distribution partner

For Besse Medical:
- Go to Besse.com to access a Besse Business Application
- Applications can be completed online; downloaded, printed, and faxed to 1-888-375-0030; or scanned and emailed to accountsetup@besse.com
- Besse Medical retains sole discretion for opening an account and establishing credit limits

When your Besse Medical account is set up, you are ready to order VIVITROL
- Order online at Besse.com
- Call 1-800-543-2111 to order by phone
- Fax your order to 1-800-543-8695

For Smith Medical Partners:
- Go to smpspecialty.com and click “Get Started” to become a customer
- Application can also be requested via email to smpsales@smpspecialty.com or by calling 1-800-292-9653
- Applications should be downloaded, printed and faxed to 630-227-9220; or scanned and emailed to smpsales@smpspecialty.com
- Include Physician’s State License and DEA Registration numbers with faxed or emailed application
- Smith Medical Partners retains sole discretion for opening an account and establishing credit limits

When your Smith Medical Partners account is set up, you are ready to order VIVITROL
- Order online at smpspecialty.com (registration required)
- Call 1-800-292-9653 to order by phone
- Fax your order to 630-227-9220

Please see Important Safety Information on page 9. Also see Prescribing Information and Medication Guide. Review the Medication Guide with your patients.
Reimbursement codes for VIVITROL® (naltrexone for extended-release injectable suspension)

Coding decisions should be made by the healthcare provider based on an independent review of the patient’s condition. Below is a list of codes you may find helpful.

ICD-10-CM Diagnosis Codes

Claims submitted for VIVITROL should include at least one (1) ICD-10-CM diagnosis code to indicate the patient’s condition. Specific diagnosis codes should represent the condition as supported by the patient’s medical record. The diagnosis codes listed below may apply for patients for whom VIVITROL may be appropriate.

<table>
<thead>
<tr>
<th>Patient Diagnosis</th>
<th>ICD-10-CM Diagnosis Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol Dependence</td>
<td></td>
</tr>
<tr>
<td>F10.20</td>
<td>Alcohol dependence, uncomplicated</td>
</tr>
<tr>
<td>F10.21</td>
<td>Alcohol dependence, in remission</td>
</tr>
<tr>
<td>F10.22</td>
<td>Alcohol dependence with intoxication</td>
</tr>
<tr>
<td>F10.23</td>
<td>Alcohol dependence with withdrawal</td>
</tr>
<tr>
<td>F10.24</td>
<td>Alcohol dependence with alcohol-induced mood disorder</td>
</tr>
<tr>
<td>F10.25</td>
<td>Alcohol dependence with alcohol-induced psychotic disorder</td>
</tr>
<tr>
<td>F10.26</td>
<td>Alcohol dependence with alcohol-induced persistent amnestic disorder</td>
</tr>
<tr>
<td>F10.27</td>
<td>Alcohol dependence with alcohol-induced persistent dementia</td>
</tr>
<tr>
<td>F10.28</td>
<td>Alcohol dependence with other alcohol-induced disorders</td>
</tr>
<tr>
<td>F10.29</td>
<td>Alcohol dependence with unspecified alcohol-induced disorder</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Opioid Dependence</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>F11.20</td>
<td>Opioid dependence, uncomplicated</td>
</tr>
<tr>
<td>F11.21</td>
<td>Opioid dependence, in remission</td>
</tr>
<tr>
<td>F11.22</td>
<td>Opioid dependence with intoxication</td>
</tr>
<tr>
<td>F11.23</td>
<td>Opioid dependence with withdrawal</td>
</tr>
<tr>
<td>F11.24</td>
<td>Opioid dependence with opioid-induced mood disorder</td>
</tr>
<tr>
<td>F11.25</td>
<td>Opioid dependence with opioid-induced psychotic disorder</td>
</tr>
<tr>
<td>F11.28</td>
<td>Opioid dependence with other opioid-induced disorder</td>
</tr>
<tr>
<td>F11.29</td>
<td>Opioid dependence with unspecified opioid-induced disorder</td>
</tr>
</tbody>
</table>

AMA, against medical advice; CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; MCC, major complications and comorbidities. These are not all of the codes available for this program. A complete list of codes can be found at www.cms.gov.

Please see Important Safety Information on page 9. Also see Prescribing Information and Medication Guide. Review the Medication Guide with your patients.
BUY-AND-BILL PROVIDERS AND THE VIVITROL®
(NALTREXONE FOR EXTENDED-RELEASE INJECTABLE SUSPENSION)
CO-PAY SAVINGS PROGRAM

How to enroll in the VIVITROL® Co-pay Savings Program

In order to enroll in the VIVITROL® Co-pay Savings Program, you must set up an account with OPUS Health.

To set up an account please follow these steps:

- Call OPUS Health at 1-877-838-3836 to get a form to fill out.
- Fax the completed form to OPUS Health at 1-877-838-3836.
- OPUS Health will provide a prepopulated payment form for use in claims submission.
  - Please allow 2 to 4 weeks for processing.

Once you are enrolled, reimbursement is simple and efficient

- Complete a VIVITROL® Co-pay Savings Program payment form for each eligible patient.
  - OPUS Health will provide a prepopulated payment form for use by the provider.
- Fax the completed form to OPUS Health at 1-877-678-7496, including:
  - Information on the co-pay card provided to the patient
  - Explanation of benefits
  - Patient copy of co-pay card (display RxID)
- Reimbursement for patient out-of-pocket (co-payment, co-insurance, or deductible) costs are sent directly to you from OPUS Health 2 to 4 weeks after submission.
  - Opus Health will contact your office if your submission is not validated.
- Call OPUS Health at 1-877-838-3836 for assistance.

If you enroll, you can be directly reimbursed for your eligible patients’ co-pay or deductible expenses.

This is not a guarantee of payment, coverage, or reimbursement. Alkermes does not provide any advice, recommendation, guarantee, or warranty relating to coverage, reimbursement, or coding for any product or service. Healthcare providers are responsible for determining coverage and reimbursement information and ensuring the accuracy and completeness of claim submissions for their patients. Coding, coverage, and reimbursement vary significantly by payer, patient, and setting of care and are subject to change. Additional information may exist. Actual coverage and reimbursement decisions are made by individual payers.

Please see Important Safety Information on page 9. Also see Prescribing Information and Medication Guide. Review the Medication Guide with your patients.
ELIGIBLE PATIENTS* CAN SAVE ON VIVITROL®
(NALTREXONE FOR EXTENDED-RELEASE INJECTABLE SUSPENSION)

The VIVITROL® Co-pay Savings Program is part of the comprehensive patient support services designed to help your eligible patients’ with out-of-pocket expenses associated with their VIVITROL prescriptions.

**The VIVITROL® Co-pay Savings Program:**
- Covers up to $500/month of VIVITROL co-pay or deductible expenses for eligible patients.* This may mean $0 co-pay or deductible expenses for your patients
- Has no income eligibility requirements
- Has no preset duration limits or expiration. The VIVITROL® Co-pay Savings Program card can be used multiple times. It never expires and remains active throughout the duration of treatment
- Allows patients to print co-pay cards directly from VIVITROLCopay.com. Patients can cut out the card and keep it in their wallet, so that they always have their ID number handy to give to a healthcare provider or pharmacy

**Who is eligible?**
Any patient with a prescription for VIVITROL for alcohol or opioid dependence who is 18 years or older with:
- Commercial health insurance
- No insurance or electing not to use commercial insurance

Who is not eligible?
Patients using federal or state healthcare programs to purchase their VIVITROL prescription, such as:
- Medicare, including Medicare Part D or Medicare Advantage plans
- Medicaid, including Medicaid Managed Care or Alternative Benefit Plans under the Affordable Care Act
- Medigap
- Veterans Administration
- Department of Defense
- TRICARE®
- State-funded programs such as medical or pharmaceutical assistance programs

→ Your eligible patients can sign up for the VIVITROL® Co-pay Savings Program by visiting VIVITROLCopay.com.

**Additional Financial Assistance Options**
If your patient is unable to cover a co-pay for VIVITROL or has no insurance, Vivitrol2gether™ may be able to help identify additional financial assistance options. Please contact Vivitrol2gether for more information. Call 1-800-VIVITROL (1-800-848-4876), 9am–8pm (EST).

---

*Eligibility for Alkermes-Sponsored Co-pay Assistance:
Offer valid only for prescriptions for FDA-approved indications. Patients must be at least 18 years old. Patients using Federal or state healthcare programs to purchase their VIVITROL prescription are not eligible for this offer. Void where prohibited by law, taxed, or restricted. Alkermes, Inc. reserves the right to extend, revoke, or amend these offers without notice.

Please see Important Safety Information on page 9. Also see Prescribing Information and Medication Guide. Review the Medication Guide with your patients.
VIVITROL is contraindicated in patients:
- Receiving opioid analgesics
- With current physiologic opioid dependence
- In acute opioid withdrawal
- Who have failed the naloxone challenge test or have
  exhibited hypersensitivity to naltrexone, poly(lactide-co-glycolide (PLG),
  carboxymethylcellulose, or any other components
  of the diluent

CONTRAINDICATIONS

VIVITROL is contraindicated in patients:
- Receiving opioid analgesics
- With current physiologic opioid dependence
- In acute opioid withdrawal
- Who have failed the naloxone challenge test or have
  exhibited hypersensitivity to naltrexone, poly(lactide-co-glycolide (PLG),
  carboxymethylcellulose, or any other components
  of the diluent

WARNINGS AND PRECAUTIONS

Vulnerability to Opioid Overdose:
After opioid detoxification, patients are likely to have
a reduced tolerance to opioids. VIVITROL blocks the
effects of exogenous opioids for approximately 28 days after administration. As the blockade wanes
and eventually dissipates completely, use of
previously tolerated doses of opioids could result in
potentially life-threatening opioid intoxication
(respiratory compromise or arrest, circulatory
collapse, etc.).

Cases of opioid overdose with fatal outcomes have
been reported in patients who used opioids at the
end of a dosing interval, after missing a scheduled
dose, or after discontinuing treatment. Patients and
caregivers should be told of this increased sensitivity
in opioid overdose.

- Although VIVITROL is a potent antagonist with a
  prolonged pharmacological effect, the blockade
  produced by VIVITROL is surmountable. The plasma
  concentration of exogenous opioids attained
  immediately following their acute administration may
  be sufficient to overcome the competitive receptor
  blockade. This poses a potential risk to individuals
  who attempt, on their own, to overcome the
  blockade by administering large amounts of
  exogenous opioids.
- Any attempt by a patient to overcome the VIVITROL
  blockade by taking opioids may lead to fatal
  overdose. Patients should be told of the serious
  consequences of trying to overcome the opioid
  blockade.

Injection Site Reactions:
- VIVITROL injections may be followed by pain,
tenderness, induration, swelling, erythema, bruising,
or pruritus; however, in some cases injection site
  reactions may be very severe.
- Injection site reactions not improving may require
  prompt medical attention, including, in some cases,
surgical intervention.

Adverse Reactions:

An opioid-free interval of a minimum of 7-10
days is recommended for patients previously
dependent on short-acting opioids.
- Patients transitioning from buprenorphine or
  methadone may be vulnerable to precipitated
  withdrawal for as long as two weeks.
- If a more rapid transition from agonist to antagonist
  therapy is deemed necessary and appropriate by the
  healthcare provider, monitor the patient closely in an
  appropriate medical setting where precipitated
  withdrawal can be managed.
- Patients should be made aware of the risk associated
  with precipitated withdrawal and be encouraged to
give an accurate account of last opioid use.

Hepatotoxicity:
Cases of hepatitis and clinically significant liver
dysfunction have been observed in association with
VIVITROL. Warn patients of the risk of hepatic injury;
advise them to seek help if experiencing symptoms of
acute hepatitis. Discontinue use of VIVITROL in
patients who exhibit acute hepatitis symptoms.

Depression and Suicidality:
- Alcohol- and opioid-dependent patients taking
  VIVITROL should be monitored for depression or
  suicidal thoughts. Alert families and caregivers to
  monitor and report the emergence of symptoms of
depression or suicidality.
- Although VIVITROL is a potent antagonist with a
  prolonged pharmacological effect, the blockade
  produced by VIVITROL is surmountable. The plasma
  concentration of exogenous opioids attained
  immediately following their acute administration may
  be sufficient to overcome the competitive receptor
  blockade. This poses a potential risk to individuals
  who attempt, on their own, to overcome the
  blockade by administering large amounts of
  exogenous opioids.
- Any attempt by a patient to overcome the VIVITROL
  blockade by taking opioids may lead to fatal
  overdose. Patients should be told of the serious
  consequences of trying to overcome the opioid
  blockade.

Intramuscular Injections:

Hypersensitivity Reactions:

Cases of opioid overdose with fatal outcomes have
been reported in patients who used opioids at the
end of a dosing interval, after missing a scheduled
dose, or after discontinuing treatment. Patients and
caregivers should be told of this increased sensitivity
in opioid overdose.

Hypersensitivity Reactions:

- Patients should be warned of the risk of
  hypersensitivity reactions, including anaphylaxis.

Intramuscular Injections:

- As with any IM injection, VIVITROL should be
  administered with caution to patients with
  thrombocytopenia or any coagulation disorder.

Alcohol Withdrawal:

- Use of VIVITROL does not eliminate nor diminish
  alcohol withdrawal symptoms.

ADVERSE REACTIONS

- Serious adverse reactions that may be associated
  with VIVITROL therapy in clinical use include severe
  injection site reactions, eosinophilic pneumonia,
  serious allergic reactions, unintended precipitation
  of opioid withdrawal, accidental opioid overdose,
  and depression and suicidality.

- The adverse events seen most frequently in
  association with VIVITROL therapy for alcohol
  dependence (ie, those occurring in ≥5% and at least
  twice as frequently with VIVITROL than placebo)
  include anxiety, vomiting, injection site reactions
  (including induration, pruritus, nodules, and swelling),
muscle cramps, dizziness or syncope, somnolence or
  sedation, anorexia, decreased appetite or other
  appetite disorders.

- The adverse events seen most frequently in
  association with VIVITROL in opioid-dependent
  patients (ie, those occurring in ≥2% and at least
  twice as frequently with VIVITROL than placebo)
  were hepatic enzyme abnormalities, injection site pain,
  nasopharyngitis, insomnia, and toothache.

You are encouraged to report side effects
to the FDA. Visit www.fda.gov/medwatch
or call 1-800-FDA-1088.
Please see Important Safety Information on page 9.
Please see enclosed Prescribing Information, including Medication Guide.